KR100809873B1 - 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 - Google Patents
자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 Download PDFInfo
- Publication number
- KR100809873B1 KR100809873B1 KR1020060038119A KR20060038119A KR100809873B1 KR 100809873 B1 KR100809873 B1 KR 100809873B1 KR 1020060038119 A KR1020060038119 A KR 1020060038119A KR 20060038119 A KR20060038119 A KR 20060038119A KR 100809873 B1 KR100809873 B1 KR 100809873B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- antigen
- αgalcer
- cell
- vaccine
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 252
- 108091007433 antigens Proteins 0.000 title claims abstract description 137
- 102000036639 antigens Human genes 0.000 title claims abstract description 134
- 239000000427 antigen Substances 0.000 title claims abstract description 132
- 210000000581 natural killer T-cell Anatomy 0.000 title claims abstract description 55
- 239000003446 ligand Substances 0.000 title claims abstract description 25
- 229940030156 cell vaccine Drugs 0.000 title description 59
- 229960005486 vaccine Drugs 0.000 claims abstract description 69
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims abstract description 58
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 90
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 86
- 201000011510 cancer Diseases 0.000 claims description 74
- 241000701161 unidentified adenovirus Species 0.000 claims description 35
- 241000700605 Viruses Species 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 241000701806 Human papillomavirus Species 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 102000003425 Tyrosinase Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- UCKDWANVYDOPEV-SVYNEFFASA-N alpha-glucuronosylceramide Chemical compound CCCCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCCCC)CO[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UCKDWANVYDOPEV-SVYNEFFASA-N 0.000 claims description 3
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 241000589972 Borrelia sp. Species 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 241000459479 Capsula Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102000005348 Neuraminidase Human genes 0.000 claims description 2
- 108010006232 Neuraminidase Proteins 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 2
- 241000224016 Plasmodium Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 108010021711 pertactin Proteins 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 2
- 101710120476 Murinoglobulin-1 Proteins 0.000 claims 2
- 108010051081 dopachrome isomerase Proteins 0.000 claims 2
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- 229940029041 HER-2/neu vaccine Drugs 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 abstract description 92
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 62
- 230000001093 anti-cancer Effects 0.000 abstract description 16
- 230000004044 response Effects 0.000 abstract description 15
- 210000002865 immune cell Anatomy 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 10
- 229940029030 dendritic cell vaccine Drugs 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 238000007920 subcutaneous administration Methods 0.000 abstract description 5
- 229930186217 Glycolipid Natural products 0.000 abstract description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 3
- 208000037819 metastatic cancer Diseases 0.000 abstract description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 138
- 241000699670 Mus sp. Species 0.000 description 124
- 210000001744 T-lymphocyte Anatomy 0.000 description 51
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 42
- 230000028993 immune response Effects 0.000 description 32
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 102100037850 Interferon gamma Human genes 0.000 description 26
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 21
- 230000004913 activation Effects 0.000 description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 description 20
- 230000003053 immunization Effects 0.000 description 20
- 230000003013 cytotoxicity Effects 0.000 description 19
- 231100000135 cytotoxicity Toxicity 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 19
- 108010002350 Interleukin-2 Proteins 0.000 description 18
- 230000005867 T cell response Effects 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000011068 loading method Methods 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 12
- 210000004691 chief cell of stomach Anatomy 0.000 description 12
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 11
- 231100000433 cytotoxic Toxicity 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000028996 humoral immune response Effects 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000006058 immune tolerance Effects 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005904 anticancer immunity Effects 0.000 description 6
- 230000005907 cancer growth Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940022399 cancer vaccine Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- -1 alpha-galactosyl Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 229940126530 T cell activator Drugs 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 150000002254 galactosylceramides Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000002794 lymphocyte assay Methods 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- BJLBUIYKSNQHQA-UHFFFAOYSA-N 1-(5-chloro-2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one Chemical compound OC1=CC=CC(C=CC(=O)C=2C(=CC=C(Cl)C=2)O)=C1 BJLBUIYKSNQHQA-UHFFFAOYSA-N 0.000 description 1
- IRPOZWRRAFKYMQ-LMIAXWKISA-N 1-O-(alpha-D-galactopyranuronosyl)-N-tetradecanoyldihydrosphingosine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](NC(=O)CCCCCCCCCCCCC)CO[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O IRPOZWRRAFKYMQ-LMIAXWKISA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 101100291915 Candida albicans (strain SC5314 / ATCC MYA-2876) MP65 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- BVARSKHQNMUXIB-WOUBZNJSSA-N L-idopyranose 6-monomycolate Chemical compound CCCCCCCCCCCCCCCCCC\C=C/CCCCCCCC\C=C/CCCCCCCCCCCCCCCCCCC[C@@H](O)[C@@H](CCCCCCCC)C(=O)OC[C@@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O BVARSKHQNMUXIB-WOUBZNJSSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- RWHPBLFPAUXKDB-FSBZVHFBSA-N N-octanoylisoglobotriaosyl ceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 RWHPBLFPAUXKDB-FSBZVHFBSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 108700023315 OspC Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001135759 Sphingomonas sp. Species 0.000 description 1
- 208000037432 Thymic tumor Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (11)
- 알파-갈락토실세라마이드, 알파-글루쿠로노실세라마이드, 포스파티딜이노시톨테트라만노사이드, 이소글로보트리헥소실세라마이드, 갱글리오사이드 GD3, 포스파티딜콜린, 베타-갈락토실세라마이드, 리포포스포글리칸, 글리코이노시톨 포스포리피드, 알파-갈락토실세라마이드의 유사체인 베타-아노머 갈락토실세라마이드 및 알파-아노머 갈락토실세라마이드, 박테리아 지질 항원으로 이루어진 군으로부터 선택된 어느 하나인 자연 살해 T 세포의 리간드를 적재한 B 세포, 상기 리간드와 항원을 적재한 B 세포 또는 상기 리간드를 적재하고 항원을 발현하는 B 세포를 포함하는 면역 치료 및 예방용 백신.
- 삭제
- 제 1항에 있어서, 상기 항원은 병원균(pathogenic bacteria), 바이러스 및 기생충을 포함하는 병원체(pathogen) 유래의 항원 또는 암 항원인 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 3항에 있어서, 병원균 유래의 항원은 백일해균(Bordetella pertussis) 항원(pertussis toxin, filamentous haemagglutinin, pertactin), 파상풍균 항원(tetanus toxoid), 디프테리아균(diphtheria) 항원(diphtheria toxoid), 헬리코박터파이로리(Helicobacterpylori) 항원(capsula polysaccharides of serogrup A, B, C, Y 및 W-135), 폐렴균(pneumococcal) 항원(Streptococcus pnemoniae type 3 capsular polysaccharide), 결핵균(tuberculosis) 항원, 콜레라(cholera) 항원(cholera toxin B subunit), 포도상구균(staphylococcal) 항원(staphylococcal enterotoxin B), 적리균(shigella) 항원(shigella polysaccharides), 보렐리아(Borrelia sp.) 항원, 칸디다(Candida albicans) 항원 및 플라스모디움(Plasmodium) 항원으로 구성된 군으로부터 선택되는 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 3항에 있어서, 바이러스 유래의 항원은 인플루엔자 바이러스(influenza virus) 항원(haemagglutinin 및 neuraminidase 항원), 인간 파필로마 바이러스(human papilloma virus, HPV) 항원(glycoprotein), 소수포성 입안염 바이러스(vesicular stomatitis virus) 항원(vesicular stomatitis virus glycoprotein), 사이토메갈로바이러스(cytomegalovirus, CMV) 항원, 간염(hepatitis)바이러스 항원(hepatitis A(HAV), B(HBV), C(HCV), D(HDV) 및 G(HGV) 항원)(core antigen and surface antigen), 호흡기 다핵체 바이러스(respiratory synctytial virus, RSV) 항원, 허피스 심플렉스 바이러스(herpes simplex virus) 항원, 인간 면역결핍 바이러스(human immunodeficiency virus, HIV) 항원(GP-120, GP-160, p18, Tat, Gag, Pol, Env) 및 그의 조합으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 3항에 있어서, 암항원은 인간 유두종 바이러스(HPV: human papilloma virus) E6/E7, gp100, 티로시나제(tyrosinase), 티로시나제-관련 단백질-1(TRP-1), 티로시나제-관련 단백질-2(TRP-2), 멜라노마 항원 유전자(MAGE: melanoma antigen gene), 뮤리노글로브린 1(MUC-1: murinoglobulin 1), 암 배아항원(CEA: carcinoembryonic antigen), p53, 알파-페토프로테인 및 Her-2/neu로 이루어진 군으로부터 선택되는 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 1항에 있어서, 항원은 펩티드, 지질다당류, 다당류, 당단백질 또는 폴리뉴클레오티드의 형태를 갖는 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 1항에 있어서, 상기 항원의 발현은 재조합 바이러스에 의해 도입되어 발현되는 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 제 8항에 있어서, 상기 재조합 바이러스는 항원을 발현하는 유전자가 도입된 아데노바이러스, 레트로바이러스, 백시니아 바이러스, 폭스 바이러스, 신드비스 바이러스(Sindbis virus)인 것을 특징으로 하는 면역 치료 및 예방용 백신.
- 삭제
- 삭제
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/718,391 US8003093B2 (en) | 2006-04-27 | 2006-04-27 | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen |
KR1020060038119A KR100809873B1 (ko) | 2006-04-27 | 2006-04-27 | 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060038119A KR100809873B1 (ko) | 2006-04-27 | 2006-04-27 | 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070105662A KR20070105662A (ko) | 2007-10-31 |
KR100809873B1 true KR100809873B1 (ko) | 2008-03-06 |
Family
ID=38819088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060038119A KR100809873B1 (ko) | 2006-04-27 | 2006-04-27 | 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100809873B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190129424A (ko) * | 2018-05-11 | 2019-11-20 | 강원대학교산학협력단 | 알파-갈락토실세라마이드 및 esat6를 적재한 b 세포를 포함하는 결핵 치료 및 예방용 세포 백신 |
KR20220070125A (ko) | 2020-11-20 | 2022-05-30 | 강원대학교산학협력단 | Bi-1 단백질 발현 억제를 통한 세포 백신의 효능 증강 방법 |
WO2023243890A1 (ko) * | 2022-06-15 | 2023-12-21 | 주식회사 셀리드 | 자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신 |
WO2024058609A1 (ko) * | 2022-09-15 | 2024-03-21 | 주식회사 셀리드 | 자연 살해 t 세포의 리간드와 항원을 적재한 말초혈액단핵세포를 포함하는 백신 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101715468B1 (ko) * | 2015-03-31 | 2017-03-13 | 서울대학교산학협력단 | 활성화 b 세포를 이용한 항원 특이적 세포 독성 t 세포 제조 방법 및 그 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030017733A (ko) * | 2001-08-22 | 2003-03-04 | (주)디엔에이정보 | 암치료 및 예방 제제 |
JP2004131481A (ja) | 1997-04-10 | 2004-04-30 | Kirin Brewery Co Ltd | α−グリコシルセラミドを含有するNKT細胞活性化剤 |
-
2006
- 2006-04-27 KR KR1020060038119A patent/KR100809873B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004131481A (ja) | 1997-04-10 | 2004-04-30 | Kirin Brewery Co Ltd | α−グリコシルセラミドを含有するNKT細胞活性化剤 |
KR20030017733A (ko) * | 2001-08-22 | 2003-03-04 | (주)디엔에이정보 | 암치료 및 예방 제제 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190129424A (ko) * | 2018-05-11 | 2019-11-20 | 강원대학교산학협력단 | 알파-갈락토실세라마이드 및 esat6를 적재한 b 세포를 포함하는 결핵 치료 및 예방용 세포 백신 |
KR102122802B1 (ko) * | 2018-05-11 | 2020-06-16 | 강원대학교산학협력단 | 알파-갈락토실세라마이드 및 esat6를 적재한 b 세포를 포함하는 결핵 치료 및 예방용 세포 백신 |
KR20220070125A (ko) | 2020-11-20 | 2022-05-30 | 강원대학교산학협력단 | Bi-1 단백질 발현 억제를 통한 세포 백신의 효능 증강 방법 |
WO2023243890A1 (ko) * | 2022-06-15 | 2023-12-21 | 주식회사 셀리드 | 자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신 |
WO2024058609A1 (ko) * | 2022-09-15 | 2024-03-21 | 주식회사 셀리드 | 자연 살해 t 세포의 리간드와 항원을 적재한 말초혈액단핵세포를 포함하는 백신 |
Also Published As
Publication number | Publication date |
---|---|
KR20070105662A (ko) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4713638B2 (ja) | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン | |
Anguille et al. | Dendritic cells as pharmacological tools for cancer immunotherapy | |
KR100995340B1 (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 | |
Cerundolo et al. | Harnessing invariant NKT cells in vaccination strategies | |
Sheng et al. | Cancer immunotherapy and nanomedicine | |
Bocchia et al. | Antitumor vaccination: where we stand | |
US9238064B2 (en) | Allogeneic cancer cell-based immunotherapy | |
AU2004266034B2 (en) | In vivo targeting of dendritic cells | |
KR100809873B1 (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 | |
Fujii et al. | Exploiting antitumor immunotherapeutic novel strategies by deciphering the cross talk between invariant NKT cells and dendritic cells | |
Moriya et al. | Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205+ dendritic cells | |
Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
US8003093B2 (en) | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen | |
Burn et al. | Harnessing NKT cells for vaccination | |
KR101055666B1 (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는 미분화 골수성 세포를 포함하는 백신 | |
JP2011102320A (ja) | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン | |
RU2420311C2 (ru) | Вакцина на основе в-клеток, нагруженных лигандом т-клеток-природных киллеров и антигеном | |
Lee et al. | T cells modified with CD70 as an alternative cellular vaccine for antitumor immunity | |
CN109069599A (zh) | 针对癌症的基于ptp的疫苗 | |
Shute | Glycolipid-Loaded Nanoparticles Harness Invariant Natural Killer T Cells for Tumor Immunotherapy | |
KR20230172384A (ko) | 자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신 | |
Iwase et al. | Comparison of Anti‐Tumor Responses against TL Positive Lymphoma Induced by Skin Grafting and Dendritic Cell Immunization | |
Nitcheu et al. | Preclinical and Clinical Development of Synthetic i NKT-Cell Glycolipid Agonists as Vaccine Adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140212 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160223 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170216 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171211 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181224 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191224 Year of fee payment: 13 |